PMID- 31807192
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 18
IP  - 6
DP  - 2019 Dec
TI  - Methylselenol producing selenocompounds enhance the efficiency of mammaglobin-A 
      peptide vaccination against breast cancer cells.
PG  - 6891-6898
LID - 10.3892/ol.2019.11010 [doi]
AB  - Previous phase I DNA-vaccine based clinical trials using Mammaglobin-A (Mam-A), a 
      human breast tumor associated antigen (TAA), demonstrated that this agent was 
      safe and efficient at treating patients with stage IV breast cancer. The 
      long-term success of cancer vaccines is limited by the diminished expression of 
      human leukocyte antigen (HLA) class I molecules in the tumor microenvironment. 
      The current study assessed the impact of various selenocompounds on the 
      expression of HLA class I molecules in THP-1 cells, an apparent proficient 
      antigen that presents a human monocyte-like cell line, and their eventual 
      activation of MamA2.1 (HLA-A2 immunodominant epitope of Mam-A) specific cytotoxic 
      CD8(+) T lymphocytes (CTLs). The results revealed that, following treatment with 
      methylselenol producing compounds [methylselenic acid (MSA) and dimethylselenide 
      (DMDSe)], the expression of HLA class-I was increased and components involved 
      with the antigen presentation machinery of THP-1 cells were upregulated. 
      Furthermore, CTLs activated by MamA2.1 peptide presenting THP-1 cells, 
      pre-treated with MSA and DMDSe, demonstrated an enhanced cytotoxicity in 
      HLA-A2(+)/Mam-A(+) AU565 and UACC-812 breast cancer cell lines when compared with 
      CTLs activated by THP-1 cells without drug treatment. However, no significant 
      cytotoxicity was observed under similar conditions in HLA-A2(+)/Mam-A(-) MCF-7 
      and MDA-MB-231 breast cancer cell lines. The results indicated that treatment 
      with methylselenol producing compounds retained antigen-dependent activation of 
      CD8(+) T cells. The data of the current study demonstrated that MSA and DMDSe 
      potentiated effector cytotoxic responses following TAA specific activation of 
      CTLs, indicating their future role as vaccine adjuvants in cancer immunotherapy.
CI  - Copyright (c) 2019, Spandidos Publications.
FAU - Babaer, Duaa
AU  - Babaer D
AD  - Department of Biological Sciences, Tennessee State University, Nashville, TN 
      37209, USA.
FAU - Zheng, Mu
AU  - Zheng M
AD  - Department of Chemistry, Tennessee State University, Nashville, TN 37209, USA.
FAU - Ivy, Michael T
AU  - Ivy MT
AD  - Department of Biological Sciences, Tennessee State University, Nashville, TN 
      37209, USA.
FAU - Zent, Roy
AU  - Zent R
AD  - Department of Medicine, Cell and Developmental Biology, Vanderbilt University 
      School of Medicine, Veterans Affairs Medical Center, Vanderbilt University, 
      Nashville, TN 37212, USA.
FAU - Tiriveedhi, Venkataswarup
AU  - Tiriveedhi V
AD  - Department of Biological Sciences, Tennessee State University, Nashville, TN 
      37209, USA.
AD  - Department of Pharmacology, Vanderbilt University, Nashville, TN 37212, USA.
LA  - eng
PT  - Journal Article
DEP - 20191018
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6876340
OTO - NOTNLM
OT  - aammaglobin-A
OT  - adjuvants
OT  - breast cancer
OT  - cancer vaccine
OT  - human leukocyte antigens
OT  - selenocompounds
EDAT- 2019/12/07 06:00
MHDA- 2019/12/07 06:01
PMCR- 2019/10/18
CRDT- 2019/12/07 06:00
PHST- 2019/05/16 00:00 [received]
PHST- 2019/09/06 00:00 [accepted]
PHST- 2019/12/07 06:00 [entrez]
PHST- 2019/12/07 06:00 [pubmed]
PHST- 2019/12/07 06:01 [medline]
PHST- 2019/10/18 00:00 [pmc-release]
AID - OL-0-0-11010 [pii]
AID - 10.3892/ol.2019.11010 [doi]
PST - ppublish
SO  - Oncol Lett. 2019 Dec;18(6):6891-6898. doi: 10.3892/ol.2019.11010. Epub 2019 Oct 
      18.